Literature DB >> 10216521

Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas.

C M Bamberger1, M Fehn, A M Bamberger, D K Lüdecke, F U Beil, W Saeger, H M Schulte.   

Abstract

The molecular mechanisms leading to increased cellular proliferation rates and, thus, tumor formation in the anterior pituitary gland are poorly understood. The cyclin-dependent kinase inhibitor p27Kip1 is a key molecule regulating the G1 phase of the cell cycle in many cell types. Furthermore, it was shown that p27 knock-out mice develop pro-opiomelanocortin-positive pituitary tumors. In an effort to clarify the role of p27 in the normal and tumorous human pituitary, we studied the expression of p27 by immunohistochemistry, using a highly specific mouse monoclonal anti-human p27 antibody. Normal pituitaries and 54 pituitary adenomas (twelve somatotrope adenomas, nine prolactinomas, twelve corticotrope adenomas, three TSH-producing tumors, six gonadotrope adenomas, six null cell adenomas, and six oncocytomas) were analyzed. p27 expression was determined semiquantitatively with regard to both the percentage of positive cells and the intensity of the staining. Normal human pituitaries showed strong expression of p27 in most nuclei. In contrast, the levels of p27 were reduced in the majority of the tumors analyzed. Twenty-two tumors (six somatotrope adenomas, five prolactinomas, four corticotrope adenomas, two TSH-producing tumors, two gonadotrope adenomas, and three null cell adenomas) were completely p27-negative. In 18 tumors, p27 expression was found in < or = 10% of the cells. In the other ten tumors, 11-80% of the cells were p27-positive. In summary, we were able to demonstrate reduced expression levels of the cell-cycle inhibitor p27 in tumors derived from all pituitary cell types. Our data indicate that p27 may be an important regulator of cellular proliferation in the anterior pituitary, the underexpression of which could play a role in pituitary tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10216521     DOI: 10.1530/eje.0.1400250

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  25 in total

1.  p19Ink4d is a tumor suppressor and controls pituitary anterior lobe cell proliferation.

Authors:  Feng Bai; Ho Lam Chan; Matthew D Smith; Hiroaki Kiyokawa; Xin-Hai Pei
Journal:  Mol Cell Biol       Date:  2014-03-31       Impact factor: 4.272

Review 2.  Pathogenesis of prolactinomas.

Authors:  Anna Spada; Giovanna Mantovani; Andrea Lania
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

3.  Cyclins D1 and D3 and topoisomerase II alpha in inactive pituitary adenomas.

Authors:  W Saeger; S Schreiber; D K Lüdecke
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

Review 4.  Familial isolated pituitary adenomas: from genetics to therapy.

Authors:  Federica Guaraldi; Roberto Salvatori
Journal:  Clin Transl Sci       Date:  2011-02       Impact factor: 4.689

5.  Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics.

Authors:  James A Balogun; Eric Monsalves; Kyle Juraschka; Kashif Parvez; Walter Kucharczyk; Ozgur Mete; Fred Gentili; Gelareh Zadeh
Journal:  Endocr Pathol       Date:  2015-03       Impact factor: 3.943

6.  EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.

Authors:  Hidenori Fukuoka; Odelia Cooper; Anat Ben-Shlomo; Adam Mamelak; Song-Guang Ren; Dave Bruyette; Shlomo Melmed
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

Review 7.  Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?

Authors:  Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

8.  p21, an important mediator of quiescence during pituitary tumor formation, is dispensable for normal pituitary development during embryogenesis.

Authors:  Pamela Monahan; Ashley D Himes; Agata Parfieniuk; Lori T Raetzman
Journal:  Mech Dev       Date:  2011-12-01       Impact factor: 1.882

9.  Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells.

Authors:  Xuegong Zhu; Katie Lee; Sylvia L Asa; Shereen Ezzat
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

10.  HMGA2 cooperates with either p27kip1 deficiency or Cdk4R24C mutation in pituitary tumorigenesis.

Authors:  Monica Fedele; Orlando Paciello; Davide De Biase; Mario Monaco; Gennaro Chiappetta; Michela Vitiello; Antonio Barbieri; Domenica Rea; Antonio Luciano; Serenella Papparella; Claudio Arra; Alfredo Fusco
Journal:  Cell Cycle       Date:  2018-01-30       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.